| abstract |
This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE 2 biosynthesis or PGE 2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE 2 include non-steroidal anti-infiammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE 2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE 2 ), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC. |